MX2023003431A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2023003431A
MX2023003431A MX2023003431A MX2023003431A MX2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
mitapivat
disintegrant
diluent
lubricant
Prior art date
Application number
MX2023003431A
Other languages
English (en)
Spanish (es)
Inventor
Cheuk- Yui LEUNG
Eric Simone
Ophelia Qiping Yin
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2023003431A publication Critical patent/MX2023003431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023003431A 2020-09-25 2021-09-24 Formulacion farmaceutica. MX2023003431A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US202163238483P 2021-08-30 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2023003431A true MX2023003431A (es) 2023-05-12

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003431A MX2023003431A (es) 2020-09-25 2021-09-24 Formulacion farmaceutica.

Country Status (10)

Country Link
US (1) US20230338283A1 (cg-RX-API-DMAC7.html)
EP (1) EP4216956A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542701A (cg-RX-API-DMAC7.html)
KR (1) KR20230074536A (cg-RX-API-DMAC7.html)
AU (1) AU2021347349B2 (cg-RX-API-DMAC7.html)
CA (1) CA3196829A1 (cg-RX-API-DMAC7.html)
IL (1) IL301596A (cg-RX-API-DMAC7.html)
MX (1) MX2023003431A (cg-RX-API-DMAC7.html)
TW (1) TW202228691A (cg-RX-API-DMAC7.html)
WO (1) WO2022067039A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) * 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태

Also Published As

Publication number Publication date
AU2021347349A1 (en) 2023-06-08
AU2021347349B2 (en) 2026-08-13
EP4216956A1 (en) 2023-08-02
TW202228691A (zh) 2022-08-01
CA3196829A1 (en) 2022-03-31
KR20230074536A (ko) 2023-05-30
WO2022067039A1 (en) 2022-03-31
US20230338283A1 (en) 2023-10-26
IL301596A (en) 2023-05-01
JP2023542701A (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
EP4706671A3 (en) Conjugated hepcidin mimetics
MA55145B1 (fr) Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EP4410291A3 (en) Erbb receptor inhibitors
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
MX2020012989A (es) Agente terapeutico para la fibrosis.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
JOP20210061A1 (ar) توصيل مستمر لبولي ببتيدات 3 تشبه أنجيوبويتين
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2020008761A (es) Productos alimenticios prebióticos en gomita.
MX2022007707A (es) Comprimidos de edoxaban.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
MY207759A (en) Pharmaceutical drug containing heterocyclidene acetamide derivative
MX2021013488A (es) Formulaciones liquidas de dosis oral de metilnaltrexona.
MX2025012658A (es) Composicion farmaceutica que contiene oseltamivir
MX2020002886A (es) Agente profilactico y/o terapeutico para enfermedades que involucran la expresion de ido.
MX2021005681A (es) Combinacion de un inhibidor de mcl-1 y midostaurina, usos y composiciones farmaceuticas de la misma.
MX2023012930A (es) Formulacion de sotorasib.
MX2018003456A (es) Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
WO2020247565A8 (en) Oral care composition
MY209611A (en) Novel composition
MX2024015597A (es) Compuesto de dihidrooxadiazinona y su uso farmaceutico
PH12021552886A1 (en) Pyrido-pyrimidin derivatives and pharmaceutical composition, for use in preventing or treating pi3 kinase related diseases, comprising same as active ingredient
PH12022550858A1 (en) Pharmaceutical composition comprising proton pump inhibitor and antacid